In a stun­ning turn­around, Bio­gen says that ad­u­canum­ab does work for Alzheimer's — but da­ta min­ing in­cites con­tro­ver­sy and ques­tions

Bio­gen has con­found­ed the biotech world one more time.

In a stun­ning about-face, the com­pa­ny and its part­ners at Ei­sai say that a new analy­sis of a larg­er dataset on ad­u­canum­ab has re­stored its faith in the drug as a game-chang­er for Alzheimer’s and, af­ter talk­ing it over with the FDA, they’ll now be fil­ing for an ap­proval of a drug that had been giv­en up for dead.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER